They are at the forefront of developing selective translation regulator inhibitors (STRIs), a new class of cancer therapies designed to tackle the complexity of cancer. Unlike traditional treatments, eFFECTOR's STRIs block the production of multiple disease-driving proteins with a single drug. By targeting the central node where cancer signaling pathways converge, eFFECTOR's STRIs inhibit aberrantly high protein production, which leads to uncontrolled growth, immune evasion, and metastasis.

Importantly, these STRIs can selectively inhibit the production of oncoproteins, immune suppression factors, and resistance mechanisms without interfering with normal, healthy cells. The company's scientific founders and management team have extensive experience in the discovery and development of cancer drugs, ensuring that eFFECTOR remains at the forefront of the emerging field of translation regulation therapeutics